Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Flputnam Investment Management Co.

Flputnam Investment Management Co. lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,316 shares of the medical equipment provider’s stock after selling 254 shares during the quarter. Flputnam Investment Management Co.’s holdings in Hologic were worth $951,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Mackenzie Financial Corp raised its holdings in Hologic by 17.3% during the fourth quarter. Mackenzie Financial Corp now owns 76,722 shares of the medical equipment provider’s stock worth $5,482,000 after purchasing an additional 11,308 shares in the last quarter. Cornercap Investment Counsel Inc. grew its position in shares of Hologic by 2.4% during the fourth quarter. Cornercap Investment Counsel Inc. now owns 26,679 shares of the medical equipment provider’s stock worth $1,906,000 after acquiring an additional 637 shares during the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Hologic during the fourth quarter worth approximately $1,057,000. Crestwood Advisors Group LLC grew its position in shares of Hologic by 28.8% during the fourth quarter. Crestwood Advisors Group LLC now owns 5,171 shares of the medical equipment provider’s stock worth $369,000 after acquiring an additional 1,155 shares during the last quarter. Finally, Simplicity Solutions LLC grew its position in shares of Hologic by 6.4% during the fourth quarter. Simplicity Solutions LLC now owns 4,576 shares of the medical equipment provider’s stock worth $327,000 after acquiring an additional 274 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on HOLX shares. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Wednesday, April 10th. UBS Group lifted their price objective on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Evercore ISI lifted their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Finally, William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $87.00.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $74.92 on Thursday. The firm has a market capitalization of $17.59 billion, a P/E ratio of 35.51, a PEG ratio of 2.54 and a beta of 1.00. Hologic, Inc. has a one year low of $64.02 and a one year high of $87.88. The company’s fifty day moving average is $75.68 and its two-hundred day moving average is $72.48. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business’s revenue was down 5.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.07 EPS. Analysts forecast that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Karleen Marie Oberton sold 14,940 shares of Hologic stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,846 shares of company stock worth $2,473,443. Corporate insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.